Reflections from FHNO 2026 | Kashmir

Amid the scenic valleys of Kashmir and the soothing waves of Dal Lake, FHNO 2026 created a meaningful space for conversations, collaboration, and shared perspectives on the future of oncology.

Our Co-founder, MD & CSO, Dr. Jayant Khandare, had the opportunity to engage with leading Indian oncologists, sharing perspectives on cancer research, innovation, and evolving approaches to cancer diagnostics.

Dr. Khandare also spoke about OncoDiscover® EMT CTC, an approach that extends CTC characterization beyond epithelial markers to identify mesenchymal and hybrid phenotypes associated with epithelial–mesenchymal transition (EMT).

By detecting EMT-associated CTCs expressing mesenchymal markers, OncoDiscover EMT CTC brings an additional dimension to CTC characterization, supporting the study of tumour heterogeneity, invasion, and dissemination.

From scientific exchange to new perspectives, conversations like these strengthen our shared commitment to advancing Indian oncology through science and innovation—and ultimately contributing to better patient care across India.

A memorable few days of science, collaboration, and inspiring conversations in the beautiful setting of Kashmir.

#FHNO2026 #HeadAndNeckCancer #Oncology #CancerResearch #CancerDiagnostics #PrecisionOncology #LiquidBiopsy #CTC #OncologyInnovation #Actorius